Mcdonald Partners LLC Grows Stock Holdings in GlaxoSmithKline plc (NYSE:GSK)

Mcdonald Partners LLC boosted its holdings in GlaxoSmithKline plc (NYSE:GSK) by 17.0% in the third quarter, Holdings Channel reports. The institutional investor owned 9,688 shares of the pharmaceutical company’s stock after acquiring an additional 1,407 shares during the quarter. Mcdonald Partners LLC’s holdings in GlaxoSmithKline were worth $370,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. First PREMIER Bank grew its stake in GlaxoSmithKline by 4.2% in the 3rd quarter. First PREMIER Bank now owns 6,413 shares of the pharmaceutical company’s stock valued at $245,000 after buying an additional 260 shares in the last quarter. Mariner LLC boosted its holdings in GlaxoSmithKline by 0.6% in the 2nd quarter. Mariner LLC now owns 44,223 shares of the pharmaceutical company’s stock valued at $1,761,000 after purchasing an additional 264 shares during the period. Cutler Capital Management LLC boosted its holdings in GlaxoSmithKline by 9.9% in the 2nd quarter. Cutler Capital Management LLC now owns 3,111 shares of the pharmaceutical company’s stock valued at $124,000 after purchasing an additional 279 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in GlaxoSmithKline by 1.1% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 27,790 shares of the pharmaceutical company’s stock valued at $1,062,000 after purchasing an additional 290 shares during the period. Finally, Ledyard National Bank boosted its holdings in GlaxoSmithKline by 3.2% in the 3rd quarter. Ledyard National Bank now owns 9,651 shares of the pharmaceutical company’s stock valued at $369,000 after purchasing an additional 300 shares during the period. Institutional investors and hedge funds own 11.86% of the company’s stock.

NYSE GSK opened at $41.02 on Friday. GlaxoSmithKline plc has a 52-week low of $33.53 and a 52-week high of $43.61. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.54 and a current ratio of 0.81. The company has a market capitalization of $110.45 billion, a P/E ratio of 17.38, a P/E/G ratio of 2.35 and a beta of 0.72. The company has a fifty day moving average of $40.44 and a 200-day moving average of $40.17.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, October 27th. The pharmaceutical company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.80 by $0.21. The business had revenue of $12.51 billion during the quarter, compared to the consensus estimate of $11.92 billion. GlaxoSmithKline had a net margin of 13.01% and a return on equity of 26.27%. As a group, analysts forecast that GlaxoSmithKline plc will post 3.06 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 13th. Shareholders of record on Friday, November 19th will be paid a $0.5234 dividend. The ex-dividend date of this dividend is Thursday, November 18th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.52. This represents a $2.09 annualized dividend and a yield of 5.10%. GlaxoSmithKline’s payout ratio is currently 87.29%.

Several research analysts have commented on GSK shares. Berenberg Bank reissued a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, November 1st. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, November 8th. Morgan Stanley reaffirmed an “equal weight” rating on shares of GlaxoSmithKline in a report on Wednesday, November 3rd. Finally, Barclays raised shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a report on Friday, November 5th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, GlaxoSmithKline has an average rating of “Hold” and an average target price of $41.00.

GlaxoSmithKline Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

Recommended Story: Price Target

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.